{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-016620","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.856654+00:00","generated_at":"2026-06-15T08:45:22.283978+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Esperion Q1 net loss $61.7M; US product revenue +27% to $17M; Currax partnership","bullets":["Total revenue $24.3M (+29% YoY); US net product revenue $17.0M (+27%); retail Rx equivalents +15% YoY.","Net loss $61.7M vs $56.7M loss in Q1 2022; diluted EPS loss $0.79 vs $0.93.","Pay-for-performance commercial partnership with Currax Pharmaceuticals to double promotional footprint.","Regulatory filings for bempedoic acid label update expected in 1H 2023 in U.S. and Europe.","Full-year 2023 operating expense guidance reaffirmed at $225-245M."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-016620","json":"https://secwatch.observer/filing/0001628280-23-016620.json","markdown":"https://secwatch.observer/filing/0001628280-23-016620.md","text":"https://secwatch.observer/filing/0001628280-23-016620.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/0001628280-23-016620-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/espr-20230509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T08:45:22.283978+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"53f0ec5b1c995bdab9896c603e54a6cac9c125b3","claim":"Esperion Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $24.3 million, net income $61.7 million, EPS $0.79. Guidance reaffirmed.","evidence_excerpt":"the clinical trials comprising the CLEAR program, the Company’s pipeline, and information about cardiometabolic disease. First Quarter 2023 Financial Results Total revenue was $24.3 million, compared to $18.8 million for the comparable period in 2022, an increase of 29%. U.S. net product revenue was $17.0 million, compared to $13.4 million for the comparable period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023016620/0001628280-23-016620-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$24.3 million"},{"label":"Net income","value":"$61.7 million"},{"label":"EPS","value":"$0.79"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}